The negative outcome of a recent clinical study testing the anti-HTRA1 Fab RG6147 for the treatment of geographic atrophy (Ph2 Gallego study)48 challenges the view that HTRA1 activity is critical for disease etiology. This evidence concerns the gene HTRA1 and atrophic macular degeneration.